secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001104659-23-089330
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Q2 net loss $5.7M; cash $24.6M; NXP900 IND cleared, Phase 1a expected Q3 2023
--------------------------------------------------------------------------------

- Cash $24.6M at June 30, 2023, up from $20.0M at Dec 31, 2022, enough into H1 2025.
- Net loss $5.7M vs $3.6M in Q2 2022; R&D expense $4.3M vs $2.5M.
- NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; data expected Q1 2024.
- NXP900 IND cleared by FDA; Phase 1a dose escalation study set to begin in Q3 2023.
- Potential NXP800 expansion into cholangiocarcinoma supported by preclinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/0001104659-23-089330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/tm2323028d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer